Targeting depression more effectively

Depression is one of the most common mental health conditions worldwide. It is estimated that around one in seven people will develop the condition at some point in their lives. Despite the wide range of available medicines, many sufferers do not adequately respond to treatment or experience unwanted side effects. There is therefore a great need for new therapeutic approaches.

The GO-Bio initial project CARE-2 pursues a new approach. Researchers at Friedrich Schiller University Jena have identified a previously unexplored biological signalling pathway that could play a central role in depression-like changes. Building on this, they have developed an innovative active substance from the group of so-called small molecules – low-molecular-weight substances that can specifically influence biological processes.

Rapid onset of action in preclinical studies

In preclinical studies, the active substance demonstrated promising properties. In mouse models, the antidepressant effect set in within 24 hours and lasted for up to seven days. The substance also proved to be well tolerated and only exhibited very low toxicity.

The underlying target molecule is of particular interest: it is produced in greater quantities, particularly under stressful conditions or in cases of depression. This could reduce the risk of side effects and misuse compared with existing treatments.

Optimisation for clinical use

However, initial pharmacokinetic studies revealed low oral bioavailability, meaning that, thus far, only a small proportion of the active substance enters the bloodstream after ingestion.

As part of the project, the researchers are therefore working with medicinal chemists to optimise the structure of the substance. The aim is to develop improved variants of the active substance that exhibit higher bioavailability whilst retaining their efficacy and selectivity.

The new derivatives will then be extensively tested in the laboratory and in preclinical models. The aim is to produce a patentable, orally available and well-tolerated antidepressant that can offer people with depression a new treatment option.

From research to practical application

The project is closely integrated into academic, clinical and pharmaceutical networks. In addition, preparations are being made for patent applications and new ventures in order to drive the further development of the active substance forward in a targeted manner. The aim is to accelerate the transfer of research findings into practical application.

To learn more about funded GO-Bio projects, visit the overview page.